HRP20220224T1 - Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom - Google Patents
Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom Download PDFInfo
- Publication number
- HRP20220224T1 HRP20220224T1 HRP20220224TT HRP20220224T HRP20220224T1 HR P20220224 T1 HRP20220224 T1 HR P20220224T1 HR P20220224T T HRP20220224T T HR P20220224TT HR P20220224 T HRP20220224 T HR P20220224T HR P20220224 T1 HRP20220224 T1 HR P20220224T1
- Authority
- HR
- Croatia
- Prior art keywords
- lymphoma
- combination
- use according
- hodgkin
- antibody
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 229960000390 fludarabine Drugs 0.000 claims 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 5
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 210000003563 lymphoid tissue Anatomy 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000011885 synergistic combination Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523862P | 2011-08-16 | 2011-08-16 | |
| EP11177660 | 2011-08-16 | ||
| EP12745883.4A EP2744826B1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti-cd19 antibody and a purine analog |
| PCT/EP2012/065904 WO2013024095A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a purine analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220224T1 true HRP20220224T1 (hr) | 2022-04-29 |
Family
ID=47714800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220224TT HRP20220224T1 (hr) | 2011-08-16 | 2012-08-14 | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
Country Status (25)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| ES2523901B1 (es) * | 2013-05-31 | 2015-12-02 | Universidad Autónoma de Madrid | Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica |
| IL249533A0 (en) * | 2014-06-16 | 2017-02-28 | Xencor Inc | Treatment of chronic lymphocytic leukemia |
| CA2951427A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| CA2986175A1 (en) * | 2015-05-26 | 2016-12-01 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| MA45124B1 (fr) * | 2016-05-30 | 2021-05-31 | Morphosys Ag | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| IL266216B2 (en) * | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| PL3630177T3 (pl) * | 2017-05-31 | 2024-04-08 | Morphosys Ag | Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem |
| WO2019011918A1 (en) | 2017-07-10 | 2019-01-17 | International - Drug - Development - Biotech | TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| WO2020150513A1 (en) * | 2019-01-17 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to enhance the selectivity and effectiveness of cancer treatments |
| KR20240131370A (ko) * | 2021-12-22 | 2024-08-30 | 인사이트 코포레이션 | 항-cd19 항체 요법을 위한 치료 패러다임 |
| WO2025012080A1 (en) | 2023-07-13 | 2025-01-16 | Christian-Albrechts-Universität Zu Kiel | Humanized anti-cd7 antibody |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US106A (en) | 1915-08-24 | Specipication | ||
| US11852A (en) | 1854-10-31 | Abraham bassford | ||
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| WO2000009160A1 (en) * | 1998-08-11 | 2000-02-24 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
| MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
| WO2003048731A2 (en) | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| MX2007015944A (es) | 2005-06-20 | 2008-03-07 | Medarex Inc | Anticuerpos cd19 y sus usos. |
| US20070136826A1 (en) * | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
| AU2006332155B2 (en) * | 2005-12-30 | 2013-01-10 | Cancer Research Technology Limited | Anti-CD19 antibodies with reduced immunogenicity |
| AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
| CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| CA2765080C (en) | 2009-06-24 | 2018-07-17 | The Feinstein Institute For Medical Research | Methods for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| RU2012109451A (ru) * | 2009-08-14 | 2013-09-27 | Роше Гликарт Аг | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном |
| EP2501237A1 (en) * | 2009-11-06 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Oral formulations of a hedgehog pathway inhibitor |
-
2012
- 2012-08-14 AU AU2012296905A patent/AU2012296905B2/en active Active
- 2012-08-14 WO PCT/EP2012/065904 patent/WO2013024095A1/en not_active Ceased
- 2012-08-14 EP EP22155604.6A patent/EP4083071A3/en active Pending
- 2012-08-14 SG SG10201606788VA patent/SG10201606788VA/en unknown
- 2012-08-14 SI SI201231992T patent/SI2744826T1/sl unknown
- 2012-08-14 EP EP12745883.4A patent/EP2744826B1/en active Active
- 2012-08-14 DK DK12745883.4T patent/DK2744826T3/da active
- 2012-08-14 RU RU2014103490A patent/RU2664462C9/ru active
- 2012-08-14 ES ES12745883T patent/ES2909720T3/es active Active
- 2012-08-14 PT PT127458834T patent/PT2744826T/pt unknown
- 2012-08-14 CN CN201280036572.4A patent/CN103703027B/zh active Active
- 2012-08-14 HU HUE12745883A patent/HUE058855T2/hu unknown
- 2012-08-14 CA CA2841738A patent/CA2841738C/en active Active
- 2012-08-14 RS RS20220314A patent/RS63121B1/sr unknown
- 2012-08-14 HR HRP20220224TT patent/HRP20220224T1/hr unknown
- 2012-08-14 JP JP2014525432A patent/JP6114273B2/ja active Active
- 2012-08-14 US US14/127,217 patent/US20140227277A1/en not_active Abandoned
- 2012-08-14 BR BR112013033916-0A patent/BR112013033916B1/pt active IP Right Grant
- 2012-08-14 MX MX2013014935A patent/MX353589B/es active IP Right Grant
- 2012-08-14 KR KR1020207014644A patent/KR20200060779A/ko not_active Withdrawn
- 2012-08-14 SM SM20220160T patent/SMT202200160T1/it unknown
- 2012-08-14 LT LTEPPCT/EP2012/065904T patent/LT2744826T/lt unknown
- 2012-08-14 KR KR1020197022418A patent/KR102117202B1/ko active Active
- 2012-08-14 KR KR1020147006942A patent/KR20140071368A/ko not_active Ceased
- 2012-08-14 PL PL12745883T patent/PL2744826T3/pl unknown
-
2014
- 2014-01-02 IL IL230295A patent/IL230295B/en active IP Right Grant
- 2014-03-12 ZA ZA2014/01835A patent/ZA201401835B/en unknown
-
2020
- 2020-04-03 US US16/839,903 patent/US20200352975A1/en not_active Abandoned
-
2022
- 2022-04-14 CY CY20221100284T patent/CY1125148T1/el unknown
-
2024
- 2024-02-20 US US18/581,959 patent/US20240424012A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220224T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
| HRP20220228T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
| HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
| BRPI0513100A (pt) | métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados | |
| GT201500105A (es) | Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| CY1116727T1 (el) | Θεραπεια πολλαπλης σκληρυνσης me laquinimod | |
| BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
| AR061122A1 (es) | Regimen de cladribina para tratar la escleorosis multiple | |
| MX377410B (es) | Antagonistas de receptores de integrina y sus metodos de uso. | |
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
| CL2013003298A1 (es) | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. | |
| BRPI0908541B8 (pt) | uso de panax quinquefolius ou uma fração do mesmo na ativação de respostas imunes inatas e adaptativas | |
| AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| AR065581A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| JP2019533682A5 (cg-RX-API-DMAC7.html) | ||
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| MX2022001966A (es) | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. | |
| EA200602047A1 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
| SV2006002342A (es) | Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida | |
| AR072951A1 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre |